UNH | Weekly | Haru Insights

The federal prosecution of Luigi Mangione, who murdered UnitedHealth Group (UNH) CEO Brian Thompson, advanced with the expected guilty plea and the introduction of incriminating evidence including a 3D-printed firearm and a manifesto citing UNH’s business model as a motive—marking the first known assassination of a U.S. corporate CEO in modern history and transforming UNH into a national symbol of healthcare industry scrutiny.
UnitedHealth Group’s divestment by Berkshire Hathaway in Greg Abel’s first full quarter as operating leader—revealed in a 13F filing—undermined the credibility of passive investment vehicles like the OMAH ETF, which had marketed itself as a Buffett-aligned portfolio, exposing a critical lag in tracking and eroding investor trust in legacy index replication strategies.

UNH’s disciplined shift in Medicare Advantage is delivering real results, with the medical care ratio dropping to 86.7% and a projected 20.4% earnings surge, proving that strategic focus on profitability can outperform growth-at-all-costs models.
Despite heightened scrutiny, UNH continues to beat earnings expectations, with rising consensus estimates and a robust capital return plan—$13 billion in 2025 and $5 billion in 2026—solidifying its status as a shareholder-first powerhouse with superior long-term income potential.
The company’s ability to maintain strong financial discipline amid external shocks underscores its operational resilience, positioning it as a rare example of stability in a volatile healthcare landscape.
UNH’s dividend yield remains above the industry average, offering investors reliable income even as broader markets fluctuate, reinforcing its appeal as a defensive play in uncertain times.
The continued execution of cost optimization initiatives signals a mature, adaptive management team capable of navigating complex regulatory and economic pressures without sacrificing performance.

UnitedHealth Group Incorporated (UNH)[Tv]